Abstract
Some drugs are limited in their clinical application due to their propensity for inducing adverse side effects. We examined some clinical chemotherapeutic agents that have pulmonary toxic effects. Carbamazepine (CBZ) is an antiepileptic agent and its long-term use is associated with interstitial pneumonia, pulmonary fibrosis, and pulmonary infiltration with eosinophilia. CBZ is persistent in the environment and is frequently detected in water systems. A new technique in toxicity screening, “toxicogenomic technology”, represents a useful approach for evaluating the toxic properties of new drug candidates early in the drug discovery process and their potential effects on the environment. To this end, we have examined gene expression profiles in BEAS-2B cells (a human bronchial epithelial cell line) following exposure to CBZ, which induced pulmonary toxicity, by using a human oligonucleotide chip. We identified 518 up- and 496 down-regulated genes whose expression had changed by more than 1.5-fold (p<0.01) following CBZ exposure. Gene Ontology (GO) analysis showed elevation in the expression of genes involved in several key biological processes related to pulmonary toxicity, such as cholesterol metabolism, cell proliferation, and cell cycle regulation. In conclusion, the present study indicates that CBZ exerts its toxicity by modulating mRNA expression in BEAS-2B cells. We suggest that genes expressed by CBZ might serve as a molecular signature, which could be used more widely when implemented in combination with more traditional techniques, for the assessment and prediction of toxicity following CBZ-exposure.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Archibald, N. et al. Carbamazepine-induced interstitial pneumonitis in a lung transplant patient. Respir. Med. 100, 1660–1662 (2006).
Wilschut, F. A. et al. Recurrent respiratory distress associated with carbamazepine overdose. Eur. Respir. J. 10, 2163–2165 (1997).
Ozkan, M., Dweik, R. A. & Ahmad, M. Drug-induced lung disease. Cleve. Clin. J. Med. 68, 782–785, 789–795 (2001).
Zhang, W., Ding, Y., Boyd, S. A., Teppen, B. J. & Li, H. Sorption and desorption of carbamazepine from water by smectite clays. Chemosphere. 81, 954–960 (2010).
Thacker, P. D. Pharmaceutical data elude researchers. Environ. Sci. Technol. 39, 193A–194A (2005).
Lienert, J., Güdel, K. & Escher, B. I. Screening method for ecotoxicological hazard assessment of 42 pharmaceuticals considering human metabolism and excretory routes. Environ. Sci. Technol. 41, 4471–4478 (2007).
Zhang, Y., Geissen, S. U. & Gal, C. Carbamazepine and diclofenac: removal in wastewater treatment plants and occurrence in water bodies. Chemosphere. 73, 1151–1161 (2008).
Carballa, M., Omil, F. & Lema, J. M. Comparison of predicted and measured concentrations of selected pharmaceuticals, fragrances and hormones in Spanish sewage. Chemosphere. 72, 1118–1123 (2008).
Sim, W. J., Lee, J. W. & Oh, J. E. Occurrence and fate of pharmaceuticals in wastewater treatment plants and rivers in Korea. Environ. Pollut. 158, 1938–1947 (2010).
Tixier, C., Singer, H. P., Oellers, S. & Müller, S. R. Occurrence and fate of carbamazepine, clofibric acid, diclofenac, ibuprofen, ketoprofen, and naproxen in surface waters. Environ. Sci. Technol. 37, 1061–1068 (2003).
Löffler, D., Römbke, J., Meller, M. & Ternes, T. A. Environmental fate of pharmaceuticals in water/sediment systems. Environ. Sci. Technol. 39, 5209–5218 (2005).
Chenxi, W., Spongberg, A. L. & Witter, J. D. Determination of the persistence of pharmaceuticals in biosolids using liquid-chromatography tandem mass spectrometry. Chemosphere. 73, 511–518 (2008).
Ferrari, B., Paxéus, N., Lo Giudice, R., Pollio, A. & Garric, J. Ecotoxicological impact of pharmaceuticals found in treated wastewaters: study of carbamazepine, clofibric acid, and diclofenac. Ecotoxicol. Environ. Saf. 55, 359–370 (2003).
Yeo, M. K. & Kim, H. E. Gene expression in zebrafish embryos following exposure to TiO2 nanoparticles. Mol. Cell. Toxicol. 6, 97–104 (2010).
Oscarson, M. et al. Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin. Pharmacol. Ther. 80, 440–456 (2006).
Seo, T. et al. ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics. 7, 551–561 (2006).
Mann, L. et al. Inhibition of specific adenylyl cyclase isoforms by lithium and carbamazepine, but not valproate, may be related to their antidepressant effect. Bipolar Disord. 11, 885–896 (2009).
Oscarson, M. et al. Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin. Pharmacol. Ther. 80, 440–456 (2006).
Hung, S. I. et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics. 16, 297–306 (2006).
Ghelardoni, S., Tomita, Y. A., Bell, J. M., Rapoport, S. I. & Bosetti, F. Chronic carbamazepine selectively downregulates cytosolic phospholipase A2 expression and cyclooxygenase activity in rat brain. Biol. Psychiatry. 56, 248–254 (2004).
Kim, W. J. et al. A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet. Genomics. 20, 249–256 (2010).
Meng, Q. W. et al. Inhibitory effect of carbamazepine on proliferation of estrogen-dependent breast cancer cells. Ai Zheng. 25, 967–973 (2006).
Makmor-Bakry, M. et al. Genetic variants in microsomal epoxide hydrolase influence carbamazepine dosing. Clin. Neuropharmacol. 32, 205–212 (2009).
Pirmohamed, M., Lin, K., Chadwick, D. & Park, B. K. TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients. Neurology. 56, 890–896 (2001).
Alfirevic, A. et al. Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster. Pharmacogenet. Genomics. 16, 287–296 (2006).
Lu, W., Li, X. & Uetrecht, J. P. Changes in gene expression induced by carbamazepine and phenytoin: testing the danger hypothesis. J. Immunotoxicol. 5, 107–113 (2008).
Delvecchio, C. J., Bilan, P., Nair, P. & Capone, J. P. LXR-induced reverse cholesterol transport in human airway smooth muscle is mediated exclusively by ABCA1. Am. J. Physiol. Lung Cell Mol. Physiol. 295, L949–957 (2008).
Pie, J. E. et al. Correlation between nutrition intake and gene expression profiles in children with asthma. Mol. Cell. Toxicol. 6, 313–319 (2010).
Song, M., Kim, Y. J. & Ryu, J. C. Phospholipidosis induced by PPARγ signaling in human bronchial epithelial (BEAS-2B) cells exposed to amiodarone. Toxicol. Sci. 120, 98–108 (2011).
Leite, S. A., Leite, P. J., Rocha, G. A., Routledge, P. A. & Bittencourt, P. R. Carbamazepine kinetics in cardiac patients before and during amiodarone. Arq. Neuropsiquiatr. 52, 210–215 (1994).
Vancheri, C., Failla, M., Crimi, N. & Raghu, G. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur. Respir. J. 35, 496–504 (2010).
Song, M., Kim, Y. J. & Ryu, J. C. Induction of ROS, p38 MAP Kinase and apoptosis via pulmonary toxic drugs. BioChip J. 3, 306–315 (2009).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Song, M., Kim, YJ. & Ryu, JC. Identification of genes induced by carbamazepine in human bronchial epithelial BEAS-2B cells. Toxicol. Environ. Health Sci. 3, 106–113 (2011). https://doi.org/10.1007/s13530-011-0085-2
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13530-011-0085-2